<DOC>
	<DOCNO>NCT02508649</DOCNO>
	<brief_summary>This double-blind , randomise , placebo-controlled , two-part adaptive clinical trial . The trial design investigate efficacy safety multiple dose regimen selepressin confirm efficacy safety one dose regimen treatment adult patient septic shock require vasopressor .</brief_summary>
	<brief_title>Selepressin Evaluation Programme Sepsis-Induced Shock - Adaptive Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<criteria>18 year age old Proven suspect infection Septic shock define hypotension require vasopressor treatment despite adequate fluid resuscitation Informed consent obtain accordance local regulation Not possible initiate trial drug treatment within 12 hour onset vasopressor treatment septic shock Primary cause hypotension due sepsis Previous severe sepsis intensive care unit admission within hospital stay Known/suspected acute mesenteric ischaemia Suspicion concomitant acute coronary syndrome base clinical symptom and/or ECG episode septic shock Chronic mechanical ventilation reason OR severe chronic obstructive pulmonary disease ( COPD ) require either continuous daily oxygen use precede 30 day mechanical ventilation ( acute exacerbation COPD ) precede 30 day Received bone marrow transplant precede 6 month chemotherapy precede 30 day lymphoma leukemia Known pregnant Decision limit full care take obtain informed consent Use vasopressin past 12 hour prior start trial drug treatment use terlipressin within 7 day prior start trial drug treatment Prior enrolment trial Prior use investigational medicinal product within last month OR plan concurrent participation clinical trial investigational drug investigational device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>